The economic impact of Staphylococcus aureus infection in New York City Hospitals

Emerging Infectious Diseases

Volumn 5, Issue 1, 1999, Pages 9-17

  Rubin, Robert J ^a   Harrington, Catherine A ^a   Poon, Anna ^a   Dietrich, Kimberly ^a   Greene, Jeremy A ^a   Moiduddin, Adil ^a  

^a LEWIN GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH CARE COST; HOSPITAL COST; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0033051132     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0501.990102     Document Type: Review

References (47)

1. Haley RW, Culver DH, White JW, Morgan WM, Emori TG. The nationwide nosocomial infection rate: a new need for vital statistics. Am J Epidemiol 1985;121:159.
2. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients, excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:1598-601.
3. Brachman PS, Dan BB, Haley RW, Hooten TM, Garner JS, Allen JR. Nosocomial surgical infections: incidence and cost. Surg Clin North Am 1980;60:15-25.
4. Centers for Disease Control and Prevention. National Nosocomial Infection Surveillance System report: data summary from October 1986-April 1996. Atlanta (GA): U.S. Department of Health and Human Services; 1996.
5. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-72.
6. Barrett FF, McGehee RF, Finland M. Methicillin-resistant Staphylococcus aureus at Boston City hospital. N Engl J Med 1968;279:441.
7. Boyce JM. Increasing prevalence of methicillin-resistant Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1990;11:639-42.
8. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS, et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-6.
9. Nosocomial enterococci resistant to vancomycin -United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-9.
10. Recommendations for preventing the spread of vancomycin resistance recommendations of the Hospital Infection Control Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 1995;44(RR12):1-13.
11. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46:624-6.
12. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:813-5.
13. Boyce JM, Jackson MM, Pugliese G, Batt MD, Fleming D, Garner JS, et al. Methicillin-resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. Infect Control Hosp Epidemiol 1994;15:105-15.
14. McManus AT, Mason AD, McManus WF, Pruitt BA. What's in a name? Is methicillin-resistant Staphylococcus aureus just another S. aureus when treated with vancomycin? Arch Surg 1989;124:1456-9.
15. Pittet D, Waldvogel FA. To control or not to control colonization with MRSA...that's the question! QJM 1997;90:239-41.
16. Teare EL, Barrett SP. Stop the ritual of tracing colonised people. BMJ 1997;314:665-6.
17. Cookson B. Controversies: is it time to stop searching for MRSA? Screening is still important. BMJ 1997;314:664-5.
18. Casewell MW. New threats to the control of methicillin-resistant Staphylococcus aureus. J Hosp Infect 1995;30 Suppl:465-71.
19. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996;17:552-7.
20. Haley RW, White JW, Culver DH, Hughes JM. The financial incentive for hospitals to prevent nosocomial infections under the prospective payment system: an empirical determination from a nationally representative sample. JAMA 1987;257:1611-4.
21. Wakefield DS, Pfaller MA, Hammons GT, Massanari RM. Use of the appropriateness evaluation protocol for estimating the incremental costs associated with nosocomial infections. Med Care 1987;25:481-8.
22. Jernigan JA, Clemence MA, Stott GA, Titus MG, Alexander CH, Palumbo CM, et al. Control of methicillin-resistant Staphylococcus aureus at a university hospital. Infect Control Hosp Epidemiol 1995;16:668-96.
23. Wakefield DS, Helms CM, Massanari RM, Mori M, Pfaller M. Cost of nosocomial infection: relative contributions of laboratory, antibiotic and per diem costs in serious Staphylococcus aureus infections. Am J Infect Control 1988;16:185-92.
24. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City-turning the tide. N Engl J Med 1995;333:229-33.
25. Frieden TR, Munsiff SS, Low DE, Willey BM, Williams G, Faur Y, et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993;342:76-9.
26. New York State Department of Health. 1995 Statewide Planning and Research Cooperative System (SPARCS) Administratively Releasable File. Albany (NY): The Department; 1997.
27. Health Care Financing Administration. Physician fee schedule (CY 1995); payment policies and relative value adjustments. Federal Register 1994;59(235):63410-635.
28. 1995 Drug Topics Red Book. Montvale (NJ): Medical Economics Company; 1995.
29. International classification of diseases, 9th revision, clinical modifier: with color symbols: ICD-9-CM. 4th ed. Salt Lake City (UT): Medicode Publications; 1994.
30. Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis 1993;16:567-73.
31. Espersen F. Identifying the patient risk for Staphylococcus aureus bloodstream infections. J Chemother 1995;7:11-7.
32. Muder R, Brennen C, Wagener M, Goetz A. Bacteremia in a long-term care facility: a five year prospective study of 163 consecutive episodes. Clin Infect Dis 1992;14:647-54.
33. Mandell GI, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practices of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995.
34. Lavery LA, Sariaya M, Ashry H, Harkless LB. Microbiology of osteomyelitis in diabetic foot ulcers. J Foot Ankel Surg 1995;34:61-4.
35. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, editors. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, Inc.; 1994.
36. Fagon JY, Chastre J, Vuagnat A, Troillet JL, Novara A, Gibert C. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996;275:866-9.
37. Papazian L, Bregeon F, Thirion X, Gregoire R, Saux P, Denis JP, et al. Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med 1996;154:91-7.
38. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8.
39. Leu HS, Kaiser DL, Mori M, Woolson RF, Wenzel RP. Hospital-acquired pneumonia: attributable mortality and morbidity. Am J Epidemiol 1989;129:1258-67.
40. Craven PC. Treating bone and joint infections with teicoplanin: hospitalization vs. outpatient cost issues. Hospital Formulary 1993;28:41-5.
41. Allen R. Cost-effectiveness issues for home TV therapy in the United States. Hospital Formulary 1993;28:37-40.
42. Arnow PM, Quimosing EM, Beach M. Consequences of intravascular catheter sepsis. Clin Infect Dis 1993;16:778-84.
43. Agency for Health Care Policy and Research. The HCUP-3 Nationwide Inpatient Sample (NIS), Release 2, 1993. Springfield (VA): National Technical Information Service; 1996.
44. Bradley SF. Methicillin-resistant Staphylococcus aureus infection. Clin Geriatr Med 1992;8:853-68.
45. McEvoy GK, editor. American hospital formulary service drug information 1997. Bethesda (MD): American Society of Health-System Pharmacists; 1997.
46. Spink WW. Staphylococcal infections and the problem of antibiotic-resistant staphylococci. Arch Int Med 1954;94:167-196.
47. Allen JD, Roberts CE, Kirby WM. Staphylococcal septicemia treated with methicillin: report of twenty-two cases. N Engl J Med 1962;266:111-6.